Abstract
Estrogen receptors (ER) and progesterone receptors (PgR) were immunohistologically investigated in 107 patients with gastric cancer who underwent curative resection. Both ER and PgR were detected only in the cancer cell nucleus. The ER positive rate was 27.7% for males and 31.0% for females, while the PgR positive rate was 9.2% for males and 11.9% for females. Clinicopathologically, the ER positive rate was slightly higher in young females and in cases of poorly differentiated gastric cancer. When cumulative survival rates were analyzed in relation to the presence or absence of receptors, the 10-year cumulative survival rate after surgery was significantly lower in the ER positive cases, being 15.7% cent, than in the ER negative cases, being 62.7%, and also significantly lower in the PgR positive cases, being 18.2%, than in the PgR negative cases, being 48.3%. The coexistence of ER and PgR in gastric cancer tissue suggests that the ER is physiologically active, or that ER positive gastric cancer is hormone-dependent. The poor prognosis of patients with receptor positive gastric cancer suggests that gastric cancer with these receptors is highly malignant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chevallier B, Heintzmann F, Mosseri V, Dauce JP, Bastit P, Graic Y, Brunelle P, Basuyau JP, Comoz M, Asselain B (1988) Prognostic value of estrogen and progesterone receptors in operable breast cancer. Result of univariate and multivariate analysis. Cancer 62:2517–2524
Stefansuciu GA, Pratola D, Sylvester R, Leclergq G, Da Costa PM, Legros N, T'Hooft MA, Verhest A, Mattheiem W, Heuson JG (1989) Relation between estrogen receptor concentration and clinical and histological factors: Their relative prognostic importance after radical mastectomy for primary breast cancer. Eur J Cancer Clin Oncol 25:319–329
Chanbers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE (1988) Estrogen and progestin receptor level as prognostic factors for survival in endometrial cancer. Gynecol Oncol 31:65–77
Fujimoto J, Fujita H, Hosoda S, Okada H, Tamaya T (1989) Prognosis of cervical cancers with reference to steroid receptors (in Japanese with English abstract). J Jpn Soc Cancer Ther 24:21–31
Tokunaga A, Kojima N, Andoh T, Matsukura N, Yoshiyasu M, Tanaka N, Ohkawa K, Shirota A, Asano G, Hayashi K (1983) Hormone receptor in gastric cancer. Eur J Cancer Clin Oncol 19:687–689
Yokozaki H, Takekura N, Takanashi A, Tabuchi J, Haruta R, Tahar E (1988) Estrogen receptors in gastric adenocarcinoma: A retrospective immunohistochemical analysis. Virchows Arch [A] 413:297–302
Fracavilla A, Di Leo A, Polimeno L, Conte D, Barone M, Fanizza G, Chiumarulo C, Rizzo G, Rubino M (1987) Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding noncancerous colonic tissue. Gastroenterology 93:1301–1306
Alford TG, Hoan MD, Geelhoed GW, Tsangaris NT, Lippman ME (1979) Steroid hormone receptors in human colon cancers. Cancer 43:980–984
Nagase N, Kohno H, Chang YC, Hayashi T, Utsumi Y, Nakamura T, Yukaya H (1989) Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. Cancer 63:112–116
Greene GL, Nolan C, Engler JP, Jensen EV (1980) Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci USA 77:5115–5119
Perrot-Applanat M, Groyer-Picard MT, Lorenzo F, Jolivet A, Vu Hai MT, Pallud C, Spyratos F, Milgrom E (1987) Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors. Cancer Res 47:2652–2661
Shimada A, Kimura S, Abe K, Nagasaki K, Adachi I, Yamaguchi K, Suzuki M, Nakajima T, Miller LS (1985) Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: Comparison with that in frozen sections. Proc Natl Acad Sci USA 82:4803–4807
Furukawa H, Iwanaga T, Hiratsuka M, Imaoka S, Fukuda I, Kabuto T, Ishikawa T, Sasaki Y, Kameyama M, Shibata T, Koyama H (1989) The significance of hormone receptors in hormone therapy for gastric cancers (in Japanese with English abstract). Jpn J Cancer Chemother 16:2156–2160
Kaplan EL, Meier P (1957) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481
Tokunaga A, Nishi K, Matsukura N, Tanaka N, Onda M, Shirota A, Asano G, Hayashi K (1986) Estrogen and progesterone receptors in gastric cancer. Cancer 57:1376–1379
Kawakami S, Kojima O, Uehara Y, Takahashi T (1989) Immunocytochemical staining of estrogen receptor in conventional formalin-fixed paraffin sections in human breast cancer (in Japanese with English abstract). J Jpn Surg Soc 90:102–107
King WJ, Greene GL (1984) Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745–747
Knight WA, Livingston RB, Gregory BJ, McGuire WL (1977) Recurrence in breast cancer. Cancer 37:4669–4671
Hahnel R, Wooding T, Vivian AB (1979) Prognostic value of estrogen receptor in primary breast cancer. Cancer 44:671–675
Brocklehurst D, Wilde CE, Finbow JAH, Brett R, Champion AE, Dewhurst DG (1989) Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer. Clin Chem 35:238–240
Harrison JD, Morris DL, Ellis IO, Jones JA, Jackson I (1989) The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer 64:1007–1010
Kitaoka H (1983) Sex hormone dependency and endocrine therapy for patients with diffuse carcinoma of the stomach (in Japanese with English abstract). Jpn J Cancer Chemother 10:2453–2460
Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 11:127–139
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsui, M., Kojima, O., Kawakami, S. et al. The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today 22, 421–425 (1992). https://doi.org/10.1007/BF00308791
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00308791